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of 180 days
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Abstract
Background: Premenopausal migraines frequently are associated with fluctuations of estrogen levels. Both, migraine
and combined hormonal contraceptives (CHC) increase the risk of vascular events. Therefore progestagen-only
contraceptives (POC) are a safer alternative. A previous short-term study demonstrated a positive impact of the
oral POC desogestrel on migraine frequency. To study the effect of the POC desogestrel 75 μg on migraine frequency,
intensity, use of acute medication and quality of life in a clinical setting over the period of 180 days.
Methods: Patients’ charts were screened for women with migraine, who had decided to use desogestrel for
contraception. Charts were included, if routinely conducted headache diaries were complete for 90 days before
treatment (baseline) and over a treatment period of 180 days. We also report about starters who stopped treatment
early, because of adverse events. Baseline data (day 1–90 before treatment) were compared with first and second
treatment period (treatment days 1–90 and days 91–180). Quality of life was evaluated using MIDAS questionnaires.
Results: Days with migraine (5.8 vs 3.6), with any kind of headache (9.4 vs 6.6), headache intensity (15.7 vs 10.7), days
with severe headache (5.4 vs 2.4) and use of triptans (12.3 vs7.8) were significantly reduced after 180 days. MIDAS score
and grade improved significantly.
Conclusion: Contraception with desogestrel 75 μg resulted in a significantly improved quality of life and a reduction
of migraine days over the observation period of 180 days. A clinically meaningful 30% reduction in pain was observed
in 25/42 (60%) participants. For counselling reasons it is of importance, that the major reduction in migraine frequency
occured during the initial 90 days, however further improvement occurs with longer duration of use. Prospective
studies are needed to confirm these results.
Keywords: Hormonal migraine; Contraception; Progestagen-only pill; Desogestrel; Migraine without aura; Headache;
Migraine with aura; Cardiovascular risk; Triptans
Background
Epidemiological data suggest that combined hormonal
contraceptives (CHC) initiate or worsen migraine and
headache in predisposed women [1-5]. The incidence of
migraine is highest during the reproductive years and
more than 50% of women report an association between
migraine attacks and their menstrual cycle [6,7]. The
reproductive phase is also the life span in which most
women need efficient contraception. Migraine with aura
(MA) and to a lesser extent migraine without aura (MO)
increase the risk for cardiovascular events, especially for
stroke [8-11]. There is a substantial elevation of these
risks in migraineurs using CHC [11-14]. The cardiovas-
cular risk associated with CHC, has been mainly attrib-
uted to the estrogen component which exerts a strong
effect on the coagulation system. Finding a well-
tolerated estrogen-free form of contraception for head-
ache patients therefore is an important issue.
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Progestagen-only pills (POP) have so far not been
found to be associated with an increased risk for
thromboembolic or ischemic events [15]. Most guide-
lines recommend progestagen-only contraception as a
safer option [16]. The POP desogestrel 75 μg (Cerazette®;
MSD Merck Sharp & Dohme AG, Luzern, Switzerland)
is used continuously and combines efficient inhibition of
ovulation with maintenance of low estrogen levels
[17,18]. Avoidance of estrogen peaks and withdrawal
could contribute to good tolerability of this contracep-
tive in migraineurs. Recently we reported a benefit of
desogestrel 75 μg on migraine and quality of life over a 3
month period of use [19,20]. The effect on frequency
and quality of life was comparable to improvements
observed with prophylactic agents. However, the obser-
vation interval was short. In the present study, we report
effects of 6 cycles desogestrel contraception on headache
frequency, intensity and use of pain medication.
Methods
This study was performed at the divison for family plan-
ning, unit of the Department of Reproductive Endocrin-
ology, University Hospital Zürich, Switzerland where one
of the authors (GM) runs an outpatient clinic for migraine
patients with need for hormonal therapy. Migraine is diag-
nosed according to the IHS (International Headache
Society) criteria by the referring neurologists from head-
ache centres in Zürich, Bad Zurzach or by the author [21].
Reasons for referral were need for contraception in
women with migraine, menstrual migraine or any form of
hormonal therapy of headaches. To allow an exact diagno-
sis of the headache type and frequency according to the
IHS our patients are principally instructed to conduct
headache diaries for 3 cycles before their first visit and to
continue after any intervention. MIDAS questionnaires
are used before interventions and in intervals of 90 days
thereafter. The majority of our premenopausal patients
have a need for efficient contraception. In the context
of the discussions around the elevated risks for cardio-
vascular disease and stroke we advise against combined
hormonal contraceptives as a first choice contraception
in migraineurs and in women aged 35 years or more.
Before starting a hormonal treatment women are
informed about risks and potential side effects which
include information about irregular bleeding and acne
with the use of desogestrel.
For the present study patients’ charts were screened
for women with migraine, who had decided to use the
POP desogestrel 75 μg and had conducted headache
diaries 90 days before initiation and over 180 days of use
of this medication. We included patients suffering from
all types of migraine. The observation period was de-
fined from July 2009 to December 2013. In a previous
study we already reported 90 day treatment data of 16
included patients. Women had to be premenopausal and
had to need effective contraception. We report about all
adverse events causing discontinuation earlier than 180
days. Exclusion criteria were: incomplete diaries, less
than 10 headache episodes during the pretreatment
period, initiation or change of prophylactic medications
during the observation and postmenopause. This re-
sulted in a drop-out rate of 26 out of 68 charts.
The diaries include information on the number of
migraine and headache days, the severity of headache,
the use of triptans and other pain medication, the use of
hormones and days with vaginal bleeding. Days of bleed-
ing were assessed to allow an exact diagnosis of the
migraine type according to the IHS criteria. Headache
severity was rated in the diaries according to a 4-point
scale (0 = no pain, 3 = severe pain). This score is easy to
understand and has been proven to be useful in daily
work with migraineurs. For ethical reasons all diaries
were anonymised before data evaluation. The evaluation
of anonymised data in our setting was accepted by the
ethical committee of the Kanton Zürich.
Primary efficacy variables were the differences in num-
ber of migraine and headache days, the difference in
pain score as well as MIDAS score and grade. Secondary
outcomes included differences in the number of all pain
medications and triptans used as well as differences in
days with pain score three. In population-based studies
of migraine- and headache sufferers in the US and UK
the MIDAS questionnaire and the MIDAS summary
scores proved to be a highly reliable means of assess-
ment of the impact of the ailment on daily life [22,23].
The total MIDAS score strongly correlates with both the
clinical evaluation of the severity of a patient’s headache
problem, and the frequency of the episodes, determined
from daily-based headache diaries [23].
Statistical analyses
Data were compared between baseline (BL) (day 1–90
before treatment) and treatment periods (TP): TP1 (day
1–90) TP2 (day 91–180). In addition all variables were
compared between TP1 and TP2. Statistical analyses
were done using IBM SPSS Statistics, version 22
(Armonk, New York, IBM Corp). Data are presented as
mean (SD). Pain intensity score was calculated as the
sum of headache intensities for baseline and each treat-
ment period according to the above mentioned 4-point
scale. For each period this sum was divided by three to
obtain a mean monthly pain score. To calculate monthly
frequencies, the numbers for each observational episode
was divided by three. Numbers of monthly migraine
days, headache days, headache intensity, days with use of
pain medication and questions of the MIDAS question-
naire were compared with Friedman’s test. Post-hoc
comparisons between single time points were performed
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using Wilcoxon’s signed rank test with Bonferroni
correction.
Results
A total of 68 women with migraine initiated contraception
with desogestrel 75 μg. Headache diaries of 42 subjects
were complete and eligible for analysis. Six patients had
stopped desogestrel because of side effects within 42 or
less days and were excluded (prolonged bleeding n = 3,
increase of headache n = 2, acne = 1) (Figure 1). Demo-
graphics and characteristics of eligible women and drop-
outs did not differ significantly (Table 1). Hormonal
contraception was used by 50% (n = 21) of the included
patients and 61% (n = 16) in the drop-out (p > 0.05).
One included woman had used a copper-device (drop-
outs: n = 0). Chronic headaches (>15 /month) were
found in 6 included patients and more than 8 triptans
were used monthly by 9 included patients. Mean age of
migraine onset was 22.4 years (SD 5.2). Two women
suffered from endometriosis. Frequency of migraine,
headache intensity, days with use of pain medication
and triptans were significantly reduced during TP2 in
comparison with BL (Table 2). Days with severe pain
declined from 5.4 (SD 4.2) to 2.4 (SD 3.5) (p < 0.001)
(Table 2). The improvements were in large parts visible
during TP1 and persisted during further follow-up. A
according to the IHS clinically meaningful 30% reduc-
tion in pain was observed in 25/42 (60%) participants,
whereas another 28% (12/42) experienced even a 50%
reduction [24,25]. We found a 255 reduction in the
sum of headache and migraine days in 55% (23/42) of
the included migraineurs. Seven of 42 patients (16%)
experienced 1–5 more headache/migraine days during
TP2 in comparison to BL. Interestingly, however, qual-
ity of life improved in five of these seven women.
Further analyses to explain this seemingly contradictory
result revealed a decrease in days with pain score 3 and
a decrease in overall pain intensity in all these five pa-
tients. Two women with more migraine attacks and with-
out improvement in the MIDAS score, decided to change
to a non-hormonal contraception after 180 days.
Table 3 demonstrates the changes in quality of life. All
MIDAS items improved significantly during 180 days of
desogestrel use (TP2). Again significant improvement
was already observed after TP1. Separate analyses for
MO and MA women revealed no differences with regard
to demographic parameters between the groups. In MO
patients significant improvements of all features (except
headache days) days were observed (Table 4). The very
small group of subjects with MA experienced significant
reductions in the number of pain medications and
triptans, MIDAS score and MIDAS grade.
Discussion
In the present study we report the effects of 180 days of
contraception with the progestin-only pill desogestrel
75 μg on headache and migraine. We observed a signifi-
cant reduction in migraine frequency, migraine inten-
sity, use of triptans and pain score. Quality of life
measured by the MIDAS score improved by more than
50%. Mean MIDAS grades were diminished by point
(Table 3). The majority of positive effects were apparent
after 90 days and small further improvements were
noted up to 180 days of use (Table 2). To our know-
ledge, we report for the first time that hormonal treat-
ment can reduce the use of triptans significantly. This
might be of relevance for women at the boarder of
medication overuse headaches. As different pathophysi-
ologies underlie MA and MO, we performed subana-
lyses for both types of headaches. In women with MO,
significant improvements for all variables except head-
ache days were observed. In the group of patients suffer-
ing from MA (n = 10) migraine days decreased by two/
month, what possibly as a result of the small group size
Figure 1 Flow diagram of the study population.
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was not significant. Significant bettermends were ob-
served with regard to use of pain medications, use of
triptans and MIDAS score and grade.
Migraine is a typical disorder with a high response rate
to placebo in controlled trials. For ethical reasons
placebo-controlled studies in the area of contraception
are not acceptable. An important strength of the present
study is the long run-in period and the evaluation not
only of migraine frequency but also of additional param-
eters, like pain intensity, use of pain medications and
quality of life. The combination of these data is a better
reflection of the overall well-being as demonstrated in
the detailed data analysis of the patients developing
more migraine in our study. The run in period of 90
days allowed a balanced overview with regard to mi-
graine frequencies which can vary markedly from month
to month. However, even if the headache diaries had
been conducted prospectively our analyses could have
generated selection or information bias. In particular, we
assume that a prospective design might have resulted in
a higher continuation rate and exclusion of less charts
with incomplete diaries. A control group of women
using other hormonal contraceptive methods would have
been of advantage.
Our findings for MO patients are in accordance with a
very recent retrospective diary-based study, demonstrat-
ing a significant reduction in migraine frequency, pain
intensity and use of pain medication with 6 months use
Table 1 Demographic and baseline characteristics of included charts (n = 42) and excluded charts (n = 26)
Demographics Included patients n = 42 Drop-out group n = 26 P - value
Mean (SD) Mean (SD)
Age (years) 35.1 (8.9) 31.1 (9.8) 0.64
Height (cm) 165.7 (6.5) 166.2 (5.7) 0.78
Weight (kg) 60.6 (8.4) 61.6 (9.0) 0.37
Systolic blood pressure (mmHG) 119.9 (12.6) 114.7 (26.1) 0.19
Diastolic blood pressure (mmHG) 73.7 (9.9) 75.7 (9.6) 0.91
Baseline characteristics
Migraine days per month 5.8 (4.3) 6.6 (3.6) 0.62
Headache Intensity /month 15.7 (7.6) 20.3 (9.5) 0.28
Age of migraine onset 22.4 (5.2) 24.2 (7.2) 0.42
Triptan users 12.3 (15.0) 12.1 (11.7) 0.71
MIDAS: Headache days 25.2 (17.2) 23.0 (12.8) 0.37
MIDAS: (Pain intensity) 6.4 (1.7) 6.7 (1.6) 0.57
MIDAS: Grade 3.5 (0.7) 3.3 (0.8) 0.38
Number (%) Number (%)
Migraine with aura 10 (24) 10 (38) 0.19
Migraine without aura 32 (76) 16 (61.1)
Table 2 Changes in migraine, frequency, intensity and use of pain medication during use of the contraceptive pill
desogestrel 75 μg over 180 days of use
Days/month Mean
baseline
(SD)
Mean
treatment TP
1(SD)
Mean treatment
TP 2 (SD)
Overall
P-value
P-value baseline
vs. TP 1
Posthoc* P-value
baseline vs. TP2
P-value TP 1
vs TP 2
Headache days 4.1 (4.5) 3.8 (4.1) 3.0 (4.1) 0.051 0.867 0.050 0.062
Migraine days 5.8 (4.3) 3.7 (3.4) 3.6 (4.0) <0.001 <0.001 0.001 0.701
Sum headache and
migraine
9.4 (5.1) 7.6 (5.5) 6.6 (5.4) 0.002 0.008 <0.001 0.130
Headache intensity 15.7 (7.6) 11.4 (7.5) 10.7 (8.0) <0.001 <0.001 <0.001 0.312
Days with headache
score 3 in 3 months
5.4 (4.2) 2.2 (2.7) 2.4 (3.5) <0.001 <0.001 <0.001 0.776
Pain medication 7.2 (5.9) 5.0 (3.3) 5.0 (4.0) 0.044 <0.001 0.015 0.751
Triptan use in 3 months 12.3 (15.0) 8.1 (9.4) 7.8 (10.2) 0.035 0.010 0.041 0.599
Baseline: 90 days before treatment; TP = treatment period. TP1: Treatment period days 1–90; TP2: Treatment period days 91–180.
*after Bonferroni correction, post-hoc p-values are significant at p < 0.017.
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of desogestrel [26]. Triptan use did not decline, which
contrasts with our result and might be related to the
lower number of included patients. The comparison
with a control group of users of a combined pill (COC)
in a long-cycle in this study is of great interest, because
both forms of contraception prevent hormone with-
drawal [26]. While migraine attacks and pain intensity
decreased significantly with the POP, headache
frequency declined with the COC regimen only. Deso-
gestrel use failed to exert a significant effect on non-
migrainous-headache in our sample and the comparative
trial. This can be explained, by our earlier reported find-
ings showing in an individual follow-up of both head-
ache and migraine, that a temporary transformation of
migraines to headaches occurs in some women [19].
Our present study with a longer observation period
however indicates that, on the long-term, these head-
aches might decline as well (p = 0.05). Although our
study includes only few women with MA, the findings
are backed by Nappi et al. who reported a significant
reduction in migraine frequency in MA patients, but did
not investigate pain intensity and quality of life [27].
Even if there is still a lack of prospective controlled tri-
als several diary-based studies indicate a positive impact
of desogestrel on migraine without aura [19,26,27]. Con-
tinuous use of COCs exerts a positive impact on head-
aches and hormone-withdrawal migraines, however POP
are much safer with regard to the cardiovascular and
thromboembolic risks [26,28-32]. The benefit of deso-
gestrel on migraine with aura, which is not typically
associated with estrogen withdrawal, has to be con-
firmed in future studies. Many migraineurs are reluctant
to use hormones as a consequence of previous bad
experience. During counselling it is helpful to know that
major improvements can be expected during 90 days of
desogestrel use. Furthermore, two trials indicate that
migraines and pain tend to improve further beyond 3
months [19,26,27]. On the other hand, patients have to
be informed that migraine rarely worsens. The clinically
meaningful 30% reduction in pain (considered by the
Table 3 Changes in quality of life measured with the MIDAS after 90 days and 180 days contraception with
desogestrel 75 μg
N = 42 Mean (SD)
Baseline
Mean
(SD) TP 1
Mean
(SD) TP 2
Overall
p-value
P-value baseline
vs. TP1
Posthoc* P-value
baseline vs. TP2
P-value TP1
vs. TP2
MIDAS SCORE 36.3 (41.9) 18.3 (38.8) 16.0 (32.8) <0.001 <0.001 <0.001 0.176
MIDAS 1: days missed at work 7.0 (15.2) 3.8 (13.6) 2.6 (10.9) <0.001 <0.001 0.002 0.093
MIDAS 2: days with >50% reduced
productivity at work
7.6 (5.4) 4.2 (4.6) 3.9 (4.9) 0.001 0.002 0.001 0.650
MIDAS 3: days without household work 6.3 (9.7) 3.6 (8.1) 2.6 (4.4) <0.001 0.002 <0.001 0.161
MIDAS 4: days with >50% reduced
productivity in household work
5.8 (6.8) 3.9 (7.0) 3.9 (8.2) 0.006 <0.009 0.046 0.766
MIDAS 5: days when family, social or
leisure activities are missed
9.8 (15.3) 3.7 (9.9) 3.1 (7.2) <0.001 <0.001 <0.001 0.481
MIDAS: Headache days 26.4 (19.3) 17.0 (15.5) 17.0 (18.1) <0.001 0.002 <0.001 0.487
MIDAS: Pain intensity (scale 0–10) 6.1 (1.7) 4.8 (1.5) 4.5 (2.0) <0.001 <0.001 <0.001 0.078
MIDAS: Grade 3.6 (0.7) 2.4 (1.0) 2.2 (1.2) <0.001 <0.001 <0.001 0.295
Baseline: before treatment, TP1: 1–90 days use of desogestrel; TP2: 91–180 days desogestrel use.
*after Bonferroni correction, post-hoc p-values are significant at p < 0.017.
Table 4 Changes in migraine and headache frequency during use of the progestin-only pill desogestrel 75 μg, comparison
between MO (n=32) and MA (10) patients
MO Mean (SD)
baseline
MA Mean (SD)
baseline
MO Mean
(SD) TP 2
MA Mean
(SD) TP 2
p-value MO baseline
vs. TP 2
p-value MA baseline
vs. TP 2
Headache days/month 4.1 (4.3) 3.8 (5.2) 3.4 (4.6) 1.9 (2.0) 0.06 0.60
Migraine days/month 5.4 (4.1) 6.8 (4.8) 3.2 (3.8) 4.6 (4.3) 0.007 0.09
Sum headache and
migraine/month
9.5 (5.6) 8.8 (3.6) 6.6 (4.4) 6.6 (4.4) <0.001 0.11
Headache intensity/
month
16.0 (8.3) 14.4 (5.4) 11.4(8.4) 8.5 (6.4) <0.001 0.24
Pain medication 6.2 (3.6) 9.8 (9.5) 4.7 (3.6) 5.8 (4.8) 0.03 0.03
Triptan use in 3 months 11.9 (11.8) 13.1 (22.2) 8.4 (10.7) 6.2 (8.6) 0.005 0.02
MO =migraine without aura, MA =Migraine with aura, baseline : days 1–90 before treatment; TP 2: days 91–180 of treatment.
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IHS as clinically meaningful) in 60% of our patients is
another argument to prefer this contraceptive method in
women with migraine [24,25]. Reduction in use of trip-
tans and other pain medications might contribute of the
prevention of medication-overuse headaches.
In daily life the degree to which a reduction in head-
ache frequency translates to decreased disability and
improved quality of life is highly relevant. The MIDAS
demonstrated highly reduced disability and significantly
improved quality of life in our patients.
Use of POP can cause a variety of bleeding patterns
including amenorrhoea, infrequent bleeding, frequent
bleeding and prolonged bleeding episodes. Unfavorable
bleeding patterns such as frequent bleeding and prolonged
bleeding occur as result of the continuous progestin effect
on the endometrium and can be a reason for withdrawal
from this form of contraception [33]. Prolonged and fre-
quent bleedings usually stop with longer duration of use
and can be treated if not.
Unanswered questions
New insights in the hormonal effects on the brain allow
speculations about mechanisms underlying our observa-
tions. Avoidance of hormone withdrawal can only ex-
plain the decline of cycle-related headaches. In contrast
to estrogens, progesterone seems to attenuate trigemino-
vascular nociception and reduces dural plasma protein
extravasation following stimulation of the trigeminal
ganglion [34-36]. Thus direct or receptor-mediated
effects of the desogestrel on the trigeminovascular sys-
tem can be postulated. The variety of responses on deso-
gestrel treatment could be a result of the genetic
variability of estrogen receptors in women, with some
polymorphisms being a significant risk factor for mi-
graine [37]. The neurological basis of migraine auras has
not yet been established, increasing evidence indicates
that they are a clinical manifestation of a cortical spread-
ing depression (CSD).
In mice the thresholds for cortical spreading depres-
sion (CSD) is lower in cycling females than in males.
This would allow to hypothesise that maintenance of
low estrogen levels induced by desogestrel might upreg-
ulate the threshold for CSD thus reduce MA attacks. A
further mechanism could be that desogestrel or its
metabolite etonogestrel, like progesterone and allopreg-
nanolone decrease cortical excitability via the GABA
-receptor [38-40].
At the moment we have no means to predict how an
individual migraineur will react on desogestrel. Outside
the study we achieved positive effects with higher dos-
ages. However, this is off-label use and cannot be gener-
ally recommended before prospective trials have been
conducted. Several trials highlight a positive effect of
desogestrel on migraine. Among neurologists it is well
known that headaches may be cycle-related, but they
rarely consider to search advice for a hormonal treat-
ment. Vice versa gynaecologists are not always aware of
the fact that hormonal treatment affects headache
frequency in predisposed women. A closer collaboration
between gynaecologic endocrinologists and headache
specialists might provide better care and safety for young
women, suffering from migraine during use of any
hormones or in association with their natural cycle.
Conclusion
In conclusion our data indicate a positive impact of des-
ogestrel 75 μg on migraine frequency, intensity, use of
pain medication and quality of life. The major improve-
ment was observed during the initial 90 days of use,
which might be important for patients’ counselling. Ran-
domised controlled trials are needed to substantiate our
results.
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